Cidara To Take Rezafungin Into Phase III In Two Severe Infection Indications
Two-week treatment data comparing the investigational echinocandin antifungal with caspofungin shows trend toward better cure rate with similar efficacy. Cidara plans Phase III trials for treatment and prevention of difficult-to-treat infections.
You may also be interested in...
Biotech says rezafungin should best existing echinocandin agents in treatment of Candida pathogen infections, while also offering needed prophylaxis improvements for leukemia and lymphoma patients.
Cidara Therapeutics said new top-line results from the Phase II trial evaluating its lead asset as a first-line antifungal treatment in patients with candidemia and invasive candidiasis supported its ongoing Phase III ReSTORE program.
The latest drug development news and highlights from our FDA Performance Tracker.